Novadip Biosciences raises €10.4M debt to advance regenerative medicine pipeline

Novadip Biosciences Closes €10.4M Debt Round

Belgian late-stage clinical biotechnology company Novadip Biosciences has raised €10.4 million in debt financing, according to a funding announcement dated September 21, 2026. The round was led by New Science Ventures, with participation from Wallonie Entreprendre, InvestBW, Vives Fund, Noshaq, Fund+, Sambrinvest, and ORSA Tech.

Company Background

Founded in 2013 in Mont Saint-Guibert, Novadip Biosciences is a spin-off of research by founder Prof. Denis Dufrane at UCLouvain and St. Luc University Hospital. The company specializes in regenerative medicine and has developed a proprietary 3M³ tissue regeneration platform.

This platform is designed to develop regenerative tissue products that heal large bone defects, bone non-union, and spine fusion in a single treatment.

Clinical Pipeline

Novadip's lead candidate, NVD003, is an autologous cell-based therapy currently in pivotal Phase 3 trials for congenital pseudarthrosis of the tibia in both the US and EU. The company's second candidate, NVDX3, is an allogenic bone grafting material that has completed Phase 1b/2a studies and has received FDA clearance to begin a Phase 2b/3 trial.

Funding History and Team

Since inception, Novadip Biosciences has raised €137 million in equity and non-dilutive funding. The company currently employs 53 people.

Funding Details

• Round type: Debt
• Amount: €10,400,000 EUR
• Announcement date: September 21, 2026
• Lead investor: New Science Ventures
• Additional investors: Wallonie Entreprendre, InvestBW, Vives Fund, Noshaq, Fund+, Sambrinvest, ORSA Tech

Strategic Implications

The debt financing provides Novadip with additional capital to advance its late-stage clinical programs without further equity dilution. With NVD003 in pivotal Phase 3 trials and NVDX3 cleared for a Phase 2b/3 trial, the company is positioned at a critical juncture in its development.

For acquisition watchers, Novadip represents a late-stage regenerative medicine asset with a differentiated platform technology and a pipeline targeting significant unmet needs in bone healing and spine fusion. The involvement of a broad syndicate of Belgian and international investors underscores continued confidence in the company's clinical trajectory.